Pluri (XTAE:PLUR) FFO


XTAE:PLUR Pluri Inc XTAE:PLUR
16 GF Score
Price ₪6.26
GF Value ₪19.28
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Pluri FFO?

FFO (Funds from operations) only applies to REITs.

XTAE:PLUR
16GF Score
Pluri Inc XTAE:PLUR
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pluri (XTAE:PLUR) Overvalued in 2026?

Based on GuruFocus' analysis, Pluri stock appears to be undervalued. The current stock price of ₪6.26 is trading 67.5% below its estimated GF Value™ of ₪19.28. GuruFocus considers Pluri to be Possible Value Trap.

Key valuation signals for XTAE:PLUR:

  • FFO:
  • GF Value™: ₪19.28 vs. price of ₪6.26 (67.5% below fair value)
  • GF Score™: 16/100 with 6 warning signs

No single metric tells the full story. See the XTAE:PLUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pluri Business Description

Other Exchanges PLUR:USA
Address MATAM Advanced Technology Park, Building No. 5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
16GF Score

Get the complete analysis for XTAE:PLUR

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪6.26
Price
₪19.28
GF Value